Company Overview
| Stock Name | Gaush Meditech |
|---|---|
| Stock Code | 02407 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 經銷廣泛的眼科醫療設備及耗材,涵蓋眼科七個亞專科,並向最終客戶提供相關技術服務;產品組合包括品牌夥伴經銷產品及自有產品,為中國眼科醫療器械市場最大國內參與者。 |
| Listing Date | 2022-12-12 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市東城區東直門南大街11號中匯廣場A座1901室 |
| Business Address (Hong Kong) | 香港銅鑼灣勿地臣街1號時代廣場2座31樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.gaush.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 51.40 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 100 shares |
| Entry Threshold | HK$ 5,140 |
| Par Value | To be extracted |
| Offer Period | 2022-11-30 to 2022-12-05 |
| Global Offering Shares | 13,068,600 shares |
| HK Public Offer Shares (Initial) | 1,307,000 shares (10.0%) |
| Public Offer Lots (Initial) | 13,070lots (Pool A6,535lots,Pool B6,535lots) |
| International Placing Shares (Initial) | 11,761,600 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 147,934,869 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 48.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 671,726,040 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 100 | HK$ 5,140 |
| 2 lots | 200 | HK$ 10,280 |
| 3 lots | 300 | HK$ 15,420 |
| 4 lots | 400 | HK$ 20,560 |
| 5 lots | 500 | HK$ 25,700 |
| 6 lots | 600 | HK$ 30,840 |
| 7 lots | 700 | HK$ 35,980 |
| 8 lots | 800 | HK$ 41,120 |
| 9 lots | 900 | HK$ 46,260 |
| 10 lots | 1,000 | HK$ 51,400 |
| 15 lots | 1,500 | HK$ 77,100 |
| 20 lots | 2,000 | HK$ 102,800 |
| 25 lots | 2,500 | HK$ 128,500 |
| 30 lots | 3,000 | HK$ 154,200 |
| 35 lots | 3,500 | HK$ 179,900 |
| 40 lots | 4,000 | HK$ 205,600 |
| 50 lots | 5,000 | HK$ 257,000 |
| 60 lots | 6,000 | HK$ 308,400 |
| 70 lots | 7,000 | HK$ 359,800 |
| 80 lots | 8,000 | HK$ 411,200 |
| 100 lots | 10,000 | HK$ 514,000 |
| 200 lots | 20,000 | HK$ 1,028,000 |
| 300 lots | 30,000 | HK$ 1,542,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,000 lots | 100,000 | HK$ 5,140,000 |
| 1,500 lots | 150,000 | HK$ 7,710,000 |
| 2,000 lots | 200,000 | HK$ 10,280,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 776.3M |
| Est. Threshold | HK$ 9.69B |
| Analysis Result | HK market cap below threshold, need +1148% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 7,603,852,267 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣191.6百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 |
|---|---|---|
| Revenue | 289,142 | 245,412 |
| Cost of sales | -107,670 | -121,889 |
| Gross profit | 181,472 | 123,523 |
| Other income and gains, net | 301 | 314 |
| Selling and distribution expenses | -26,128 | -51,114 |
| Administrative expenses | -16,116 | -17,688 |
| Operating profit | 121,707 | 36,012 |
| Net finance costs | -479 | -668 |
| Profit before tax | 121,228 | 35,344 |
| Income tax expense | -22,659 | -9,979 |
| Profit for the year | 98,569 | 25,365 |
| Profit attributable to owners | 98,569 | 25,365 |
Balance Sheet
| Item | 2019 | 2020 |
|---|---|---|
| Cash and cash equivalents | 104,478 | 105,978 |
| Trade and bills receivables | 30,637 | 23,256 |
| Inventories | 40,797 | 43,544 |
| Total current assets | 193,036 | 216,498 |
| Total assets | 263,352 | 300,945 |
| Total current liabilities | 25,034 | 72,040 |
| Total liabilities | 134,128 | 142,387 |
| Total equity | 129,190 | 158,558 |
| Equity attributable to owners | 129,182 | 158,550 |
Cash Flow Statement
| Item | 2019 | 2020 |
|---|---|---|
| Net cash from operating activities | 78,395 | 86,857 |
| Net cash from investing activities | -16,394 | -80,550 |
| Net cash from financing activities | -4,952 | -6,215 |
| Net increase in cash | 57,049 | 92 |
| Depreciation of PP&E | 1,755 | 2,860 |
| Depreciation of right-of-use assets | 4,968 | 5,705 |
| Amortisation of intangible assets | 639 | 845 |
| Purchase of PP&E | -15,181 | -5,052 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 51.4 |
|---|---|
| First Day Open | HK$ 51.2 |
| First Day Change | -90.47% |
| First Day Volume | 521800.0 |
| First Day Turnover | 26102400.0 |
| Use of Proceeds | 1、約38.2%或108.1百萬港元將于上市后兩年內用于提高我們的研發能力及加速我們的專利商業化;
2、約29.0%或82.1百萬港元將于上市后兩年內用于提高我們的產能及增強我們的制造能力;
3、約9.5%或26.9百萬港元將于上市后兩年內用于透過聘請專門從事眼科醫療器械銷售及營銷的人員;
4、約10.6%或30.0百萬港元將用作我們的營運資金及一般企業用途;
5、約12.7%或36.0百萬港元將用于償還我們就收購泰靚所產生利率為5%的夾層融資貸款。 |
Underwriting Syndicate
Joint Bookrunners (5)
Joint Lead Managers (7)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | CL Kiwi Holding Ltd. | 39,135,960 HKD | — | 5.83% | — | 6 months | 2023-06-12 |
| 2 | 江苏中德服贸产业投资基金(有限合伙) | 15,260,660 HKD | — | 2.27% | — | 6 months | 2023-06-12 |
| 3 | 无锡高视创业投资合伙企业(有限合伙) | 7,432,440 HKD | — | 1.11% | — | 6 months | 2023-06-12 |
| 4 | 无锡视高股权投资合伙企业(有限合伙) | 262,217,100 HKD | — | 39.04% | — | 6 months | 2023-06-12 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 高鐵塔 | — |
| Company Secretary | 李文奇、梁瑞冰 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 高鐵塔通過GT HoldCo持股42.76%;OrbiMed Asia持股12.19%;Cuprite Gem持股7.69%(緊隨全球發售完成後,假設超額配股權未獲行使) |
|---|




